Prusogliptin

Prusogliptin

Prusogliptin is a pharmacological agent used in the treatment of Type 2 diabetes. It belongs to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), which work by increasing the levels of insulin produced by the body and reducing the amount of glucose produced and released by the liver.

Mechanism of Action

Prusogliptin, like other DPP-4 inhibitors, works by blocking the action of an enzyme called dipeptidyl peptidase-4. This enzyme is involved in the breakdown of a hormone called incretin, which stimulates the release of insulin in response to a meal. By inhibiting the action of DPP-4, Prusogliptin increases the levels of incretin hormones in the body, leading to increased insulin production and decreased glucose production.

Clinical Use

Prusogliptin is used in the management of Type 2 diabetes, a condition characterized by high blood glucose levels. It is typically prescribed when diet and exercise alone do not provide adequate control of blood glucose levels. Prusogliptin may be used alone or in combination with other antidiabetic medications.

Side Effects

Common side effects of Prusogliptin include nausea, vomiting, diarrhea, and abdominal pain. In rare cases, it may cause pancreatitis or severe joint pain.

Contraindications

Prusogliptin is contraindicated in patients with a history of hypersensitivity to the drug or any of its components. It is also contraindicated in patients with Type 1 diabetes or diabetic ketoacidosis, as it has not been studied in these populations.

See Also

• Dipeptidyl peptidase-4 inhibitors
• Type 2 diabetes
• Insulin
• Glucose

‎